Skip to main content
Equibles

TRXB · TRex Bio, Inc.

Track TRXB — free

Use TRXB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TRXB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.44 -0.36 (-2.43%) At close · Oct 20
Rebalance outlook locked
Market Cap
$396.32M
Shares
27.45M
Volume · Oct 20 64.23K Avg daily vol (8 sessions) 290.28K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.44 Open$14.80 Day$14.22–15.01 Available close range$13.50–14.80 Avg vol available · 8d290K Short vol31% DataOct 2026–Oct 2026

The closing range uses available history since Oct 9, 2026; less than a full year is stored.

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross No cross
52-week position 72%
mid-range
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 55%
annualized · 1-yr
Max drawdown −4%
past year

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
0 · 2 · 0
50 / 200-day cross
No cross Neutral
52-week position
72% Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its available closing range
Range low $14 Now $14 · 72% Range high $15

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TRXB
TRex Bio, Inc.
this stock
$396.32M — — — —
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Volume
Short vol %
31%
As of
Oct 20, 2026
Short Total
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 13, 2026
This year
3

Following its IPO consummation on October 13, 2026, TRex Bio, Inc. authorized 225 million common shares and 25 million undesignated preferred shares, eliminated prior preferred-stock series and stockholder action by written consent.

View
Earnings & Events
Investor Relations
Latest news
TRexBio Announces Closing of Init…
Published
Oct 13, 2026
View

Performance

5D 20D 120D MTD YTD
TRXB +6.2% — — — —
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY +7.3% — — — —
Key facts CIK 2139097 Visit website Investor relations